This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

North American Nuclear Medicine / Radiopharmaceutical Market Worth $5.55 Billion By 2017

DALLAS, April 10, 2013 /PRNewswire/ --

The  " North American Nuclear Medicine/Radiopharmaceuticals Market  & Stable Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13)  -  Forecast to 2017" analyzes and studies the major market drivers, restraints, and opportunities in North America, Latin America, Europe, Asia, and Rest of the World.

Browse
  • 120  market data tables
  • 29  figures
  • 280  pages and an in-depth Table of Content on "North American Nuclear Medicine / Radiopharmaceutical Market"

http://www.marketsandmarkets.com/Market-Reports/north-american-nuclear-medicine-radiopharmaceuticals-market-1108.html

Early buyers will receive 10% customization on this report.

This report studies the North American nuclear medicine market over the forecast period 2012-2017.

The North American radiopharmaceutical market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%. It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 15% in mature markets such as North America, between 2010 and 2030, however shortage of Mo-99/Tc-99m has been a threat to this industry. The scheduled shutdown of the NRU reactor in 2016 is a major risk for manufacturers in the near future. Companies have increased the production of thallium to meet the shortage, as it is the most commonly used substitute for technetium-99 in cardiac-stress tests, conducted to evaluate the functioning of coronary arteries. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.

Increasing use of SPECT and PET scans, technical advancements in equipment and other factors such as rising awareness of radiopharmaceuticals among physicians, alpha radio immunotherapy based targeted cancer treatment, and ready availability of north american nuclear medicine / radiopharmaceutical market from cyclotrons have driven the market. High cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals are major hurdles to growth of the market.

North America is the dominant market for diagnostic radioisotopes. The U.S. is the largest consumer market for radiopharmaceuticals, while Canada is one of the largest producers of Tc-99m.

Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. ( Canada), and Triad Isotopes, Inc. (U.S.), Cardinal Health dominated with more than 40% share in 2012.

The stable isotopes market was less than $50 million in 2012 and poised to grow at high double digit CAGR in the next 5 years. Carbon-13 commanded the largest share of the global stable isotope market in 2012; however deuterium and oxygen show tremendous potential to grow in the near future. The market was dominated by two players, Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) in 2012 jointly contributing more than 90% to the North America revenue.

Buy a copy of this report @ http://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=1108

Browse related reports to P harmaceutical  Market @ http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html

About MarketsandMarkets

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,672.89 -10.69 -0.06%
S&P 500 2,064.26 -4.50 -0.22%
NASDAQ 4,953.3990 -38.5410 -0.77%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs